NCT06467084 - Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions

Hereditary Angioedema

Interventions

DRUG

KVD900 150 mg

KVD900 Tablet 150 mg (2 x 75 mg)

DRUG

KVD900 300 mg

KVD900 Tablet 300 mg (1 x 300 mg)

DRUG

KVD900 600 mg

KVD900 Tablet 600 mg (2 x 300 mg)

Trial Locations (24)

13005

COMPLETED

KalVista Investigative Site, Marseille

17011

COMPLETED

KalVista Investigative Site, Hershey

20097

ACTIVE_NOT_RECRUITING

KalVista Investigative Site, Milan

20902

RECRUITING

KalVista Investigative Site, Wheaton

31048

ACTIVE_NOT_RECRUITING

KalVista Investigative Site, Haifa

35128

ACTIVE_NOT_RECRUITING

KalVista Investigative Site, Padua

35209

RECRUITING

KalVista Investigative Site, Birmingham

43560

COMPLETED

KalVista Investigative Site, Toledo

47715

RECRUITING

KalVista Investigative Site, Evansville

59000

ACTIVE_NOT_RECRUITING

KalVista Investigative Site, Lille

60590

ACTIVE_NOT_RECRUITING

KalVista Investigative Site, Frankfurt am Main

60596

COMPLETED

KalVista Investigative Site, Frankfurt am Main

63141

RECRUITING

KalVista Investigative Site, St Louis

75012

ACTIVE_NOT_RECRUITING

KalVista Investigative Site, Paris

75231

COMPLETED

KalVista Investigative Site, Dallas

85251

RECRUITING

KalVista Investigative Site, Scottsdale

90404

RECRUITING

KalVista Investigative Site, Santa Monica

92123

RECRUITING

KalVista Investigative Site, San Diego

4920235

COMPLETED

KalVista Investigative Site, Petah Tikva

6423906

ACTIVE_NOT_RECRUITING

KalVista Investigative Site, Tel Aviv

T6G 2B7

ACTIVE_NOT_RECRUITING

KalVista Investigative Site, Edmonton

00133

ACTIVE_NOT_RECRUITING

KalVista Investigative Site, Rome

350-8550

COMPLETED

KalVista Investigative Site, Kawagoe

113-8431

ACTIVE_NOT_RECRUITING

KalVista Investigative Site, Tokyo